EuroEyes Soars on Debut in Hong Kong

The video discusses the company's market presence in Germany and China, highlighting its leadership in refractive surgery and eye diseases. It explains the financial strategy, including a 25% capital increase and successful IPO, aimed at expanding in China. The company differentiates itself by using German technology and surgeons. Advancements in refractive surgery, such as LASIK and trifocal lenses for presbyopia, are covered. Expansion plans focus on first-tier and smaller cities in China, addressing regulatory challenges. Liability and patient care are managed internally. The company reports strong financial performance, with significant growth expected in China.

How does the company differentiate itself from competitors in China?

What challenges does the company face regarding government policies in China?

What are the company's future expansion plans in China?